Table 4. Achievement of MRD response... | American Society of Hematology

Table 4.

Achievement of MRD response (MRD⁻ at ≥2 consecutive assessments) among patients who were MRD⁺ at baseline

Placebo	Oral-AZA	Placebo
MRD⁺ at baseline, N	103	116
*MRD responders, n (%)**	38/103 (37)	22/116 (19)
OR [95% CI], Oral-AZA vs placebo	2.50 [1.35, 4.61]
Time to MRD response,†n (%)*
≤3 mo	22/38 (58)	15/22 (68)
>3 to ≤6 mo	7/38 (18)	6/22 (27)
>6 mo	9/38 (24)	1/22 (5)

Placebo	Oral-AZA	Placebo
MRD⁺ at baseline, N	103	116
*MRD responders, n (%)**	38/103 (37)	22/116 (19)
OR [95% CI], Oral-AZA vs placebo	2.50 [1.35, 4.61]
Time to MRD response,†n (%)*
≤3 mo	22/38 (58)	15/22 (68)
>3 to ≤6 mo	7/38 (18)	6/22 (27)
>6 mo	9/38 (24)	1/22 (5)

AZA, azacitidine; CI, confidence interval; mo, months; MRD, measurable residual disease; OR, odds ratio.

MRD response was defined as patients where were MRD⁺ at baseline and became MRD⁻ on treatment.

Time from randomization.